Evaxion to present at numerous upcoming conferences

Rhea-AI Summary

Evaxion Biotech (NASDAQ: EVAX), a clinical-stage TechBio company focused on AI-Immunology™ powered vaccines, has announced its participation in multiple scientific and investor conferences across the US and Europe during March-June 2025.

The company will deliver scientific and corporate updates at key events including:

• Immunotherapy and Immuno-Oncology Congress in London (March 12-14)
• HC Wainwright AI Based Drug Discovery Conference (Virtual, April 2)
• World Vaccine Congress in Washington (April 21-25)
• AACR Annual Meeting in Chicago (April 25-30)
• BIO International Convention in Boston (June 16-19)

These conferences are strategically important for Evaxion to identify potential business partnerships and scientific collaborations. The company will also attend additional conferences without presenting to enhance stakeholder engagement.

• Evaxion will provide company and scientific updates at conferences in both the US and Europe during the coming weeks and months
  
  

COPENHAGEN, Denmark, March 4, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will be presenting at several investor and scientific conferences in March and throughout the second quarter of 2025.

Evaxion will be providing company and scientific updates as well as engaging with different stakeholders at conferences in both the US and Europe. As such, conference participation is an important part of our strategy to identify potential partners and opportunities for both business partnerships and scientific collaborations.

Evaxion conference participation March-June 2025:

Immunotherapy and Immuno-Oncology Congress, March 12-14 - London

HC Wainwright AI Based Drug Discovery & Development Conference, April 2 - Virtual

Jones Healthcare and Technology Innovation Conference, April 8-9 - Las Vegas

World Vaccine Congress, April 21-25 - Washington

AACR Annual Meeting, April 25-30 - Chicago

Sidoti Micro-Cap Conference, May 20-21 - Virtual

Dark Genome Target Discovery & Development Summit, June 16-18 - Boston

BIO International Convention, June 16-19 - Boston

World Conference on Infectious Diseases, June 18-20 - Stockholm

International Neoantigen Summit, June 24-26 - Amsterdam

In addition to the list above, Evaxion will be participating, but not presenting, at additional conferences to further boost our stakeholder engagement. Please visit our website for more information.

Contact information 
Evaxion Biotech A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai 

About EVAXION
Evaxion Biotech A/S is a pioneering TechBio company based upon its AI platform, AI-Immunology™. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology™, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients’ lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology™ platform and vaccine pipeline, please visit our website.

Forward-looking statement 
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geo-political and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law. 

FAQ

What conferences will Evaxion (EVAX) attend in Q2 2025?

In Q2 2025, EVAX will attend multiple conferences including World Vaccine Congress (Washington), AACR Annual Meeting (Chicago), Sidoti Micro-Cap Conference (Virtual), Dark Genome Summit (Boston), BIO Convention (Boston), and conferences in Stockholm and Amsterdam.

Where will Evaxion (EVAX) present its AI-Immunology vaccine updates in March 2025?

EVAX will present at the Immunotherapy and Immuno-Oncology Congress in London from March 12-14, 2025.

How many conferences is Evaxion (EVAX) scheduled to present at between March and June 2025?

EVAX is scheduled to present at 10 major conferences across the US and Europe between March and June 2025, with additional conference attendance planned without presentations.

What is the strategic purpose of Evaxion's (EVAX) conference participation in 2025?

EVAX's conference participation aims to provide company updates, deliver scientific presentations, and identify potential business partnerships and scientific collaborations.